Progress on cholesterol metabolism and non-alcoholic steatohepatitis

doi:10.16352/j.issn.1001-6325.2022.07.1134

Abstract

Abstract: Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD). Cholesterol is an essential substance for biological process. Intestinal absorption of dietary cholesterol, as well as circulating lipoprotein exchange, intracellular cholesterol synthesis and metabolism influence hepatic lipid metabolism. It is indicated that the dysfunction of organelles and the secretion of inflammatory cytokines contributed to the activation of cholesterol-loaded macrophage. Besides, cholesterol and bile acid metabolism can also trigger to the development and progression of NASH.

Key words: cholesterol, non-alcoholic steatohepatitis, macrophage, inflammation, bile acid

CLC Number:

R589

LI Xiao-xiao, SHU Xiang-bing, ZHANG Li. Progress on cholesterol metabolism and non-alcoholic steatohepatitis[J]. Basic & Clinical Medicine, 2022, 42(7): 1134-1138.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2022.07.1134

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2022/V42/I7/1134

References 21

[1]	Nihei W, Nagafuku M, Hayamizu H, et al. NPC1L1-dependent intestinal cholesterol absorption requires ganglio-side GM3 in membrane microdomains[J]. J Lipid Res, 2018, 59: 2181-2187.
[2]	Zuo H, Su X, Jin Y, et al. Transthyretin regulated by linc00657/miR-205-5p promoted cholesterol metabolism by inducing SREBP2-HMGCR and inhibiting LXR alpha-CYP7A1[J]. Arch Med Res, 2020, 51: 317-326
[3]	McGettigan B, McMahan R, Orlicky D, et al. Dietary lipids differentially shape nonalcoholic steatohepatitis progression and the transcriptome of Kupffer cells and infiltrating macrophages[J]. Hepatology, 2019, 70: 67-83.
[4]	Chen HW, Yen CC, Kuo LL, et al. Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells[J]. Toxicol Appl Pharmacol, 2020, 393: 114941. doi: 10.1016/j.taap.2020.114941.
[5]	Bakke SS, Aune MH, Niyonzima N, et al. Cyclodextrin reduces cholesterol crystal-induced inflammation by modulating complement activation[J]. J Immunol, 2017, 199: 2910-2920.
[6]	Ho CM, Ho SL, Jeng YM, et al. Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease[J]. J Inflamm, 2019, 16: 7. doi: 10.1186/s12950-019-0211-5.
[7]	庄红, 张苏川, 刘慧地, 等. 沉默CXCL12抑制ox-LDL小鼠巨噬细胞系RAW264.7泡沫化和凋亡[J]. 基础医学与临床, 2021, 41:219-224.
[8]	Ioannou GN, Van Rooyen DM, Savard C, et al. Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH[J]. J Lipid Res, 2015, 56: 277-285.
[9]	Yu Y, Liu Y, An W, et al. STING-mediated inflamma-tion in Kupffer cells contributes to progression of nonalcoholic steatohepatitis[J]. J Clin Invest, 2019, 129: 546-555.
[10]	Dang EV, McDonald JG, Russell DW, et al. Oxysterol restraint of cholesterol synthesis prevents AIM2 inflammasome activation[J]. Cell, 2017, 171: 1057-1071.
[11]	Domínguez-Pér milton C, Mortensen R, et al. Trafficking of cholesterol to the ER is required for NLRP3 inflammasome activation[J]. J Cell Biol, 2018, 217: 3560-3576.
[13]	Guo C, Chi,Z, Jiang D, et al. Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages[J]. Immunity, 2018, 49: 842-856.
[14]	Di Rocco M, Pisciotta L, Madeo A, et al. Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency[J]. Orphanet J Rare Dis, 2018, 13: 24. doi: 10.1186/s13023-018-0768-8.
[15]	Fiorucci S, Biagioli M, Sepe V, et al. Bile acid modu-lators for the treatment of nonalcoholic steatohepatitis (NASH)[J]. Expert Opin Investig Drugs, 2020, 29: 623-632.
[16]	Fiorucci S, Di Giorgio C, Distrutti E. Obeticholic acid: an update of its pharmacological activities in liver dis-orders[J]. Handb Exp Pharmacol, 2019, 256: 283-295.
[17]	Briand F, Brousseau E, Quinsat M, et al. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the diet-induced NASH (DIN) hamster model[J]. Eur J Pharmacol, 2018, 818: 449-456.
[18]	Carino A, Marchianò S, Biagioli M, et al. Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis[J]. Faseb J, 2019, 33: 2809-2822.
[19]	Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites[J]. Gut, 2021, 70: 761-774.
[20]	Beaumont M, Neyrinck AM, Olivares M, et al. The gut microbiota metabolite indole alleviates liver inflammation in mice[J]. Faseb j, 2018, 32: fj201800544. doi: 10.1096/fj.201800544.
[21]	Canyelles M, Tondo M, Cedó L, et al. Trimethylamine N-oxide: a link among diet, gut microbiota, gene regulation of liver and intestine cholesterol homeostasis and HDL function[J]. Int J Mol Sci, 2018, 19: 3228. doi: 10.3390/ijms19103228.

[1]	WANG Shan, YANG Hua-yu, SUN Ying, MA Qing. Correlation between serum miR-21 expression and T cells in elderly dialysis patients [J]. Basic & Clinical Medicine, 2022, 42(8): 1188-1193.
[2]	WANG Yuan-zhuo, ZHENG Qing-yue, ZHANG Han-lin, QIU Wen-ying, WANG Tao, MA Chao. Function of the microglia in neuroinflammation of Alzheimer's disease:a brief review [J]. Basic & Clinical Medicine, 2022, 42(8): 1310-1313.
[3]	JIANG Xiu-fang, GENG Ya-nan, YANG Sheng-hong, WEI Ping, ZHAO Ming, ZHU Ling-ling. Gypenoside alleviates injury of rat adrenal pheochromocytoma cell line PC12 induced by lipopolysaccharide [J]. Basic & Clinical Medicine, 2022, 42(6): 908-912.
[4]	MA Rui, YANG Li-xing, CHEN Qiu-xia, QIU Jia-xing, WANG Yu-cheng, JU Rui, GUO Lei. Effects of carboxyamidotriazole-orotate on oncogenic phenotypes of mouse glioma-associated macrophage cell lines [J]. Basic & Clinical Medicine, 2022, 42(5): 701-707.
[5]	KANG Jin-yu, LUO Jia, GAO Ze-tian, ZHENG Wen-tao, LIU Ai-ming, SONG Yu-fei. Research progress on the inflammatory mechanisms of cholestatic liver injury [J]. Basic & Clinical Medicine, 2022, 42(5): 809-813.
[6]	LI Rong, ZHU Han-yue. Ketorolac tromethamine inhibits inflammation in rat models with knee osteoarthritis [J]. Basic & Clinical Medicine, 2022, 42(3): 417-422.
[7]	WANG Hui-juan, WANG Ji-hong, ZHAO Xing-shan, LIU Wei. Effect of pitavastatin on levels and functions of HDL-C in patients with stable coronary artery disease and dyslipidemia [J]. Basic & Clinical Medicine, 2022, 42(3): 467-471.
[8]	ZHANG Qi-yue, ZHANG Wei-li. The role of vascular aging in atherosclerosis [J]. Basic & Clinical Medicine, 2022, 42(3): 372-377.
[9]	HAN Shuang, CHEN Yu, ZHANG Wei-li. Effect of miR-216a on macrophages derived from human peripheral blood mononuclear cells [J]. Basic & Clinical Medicine, 2022, 42(3): 384-388.
[10]	HU Xian-liang, WAN Yan, FENG Ji. Research progress of gut microbiota in the pathogenesis of gestational diabetes mellitus [J]. Basic & Clinical Medicine, 2022, 42(3): 516-519.
[11]	YANG Jia-hui, ZHAO Wei, XIE Xiang-hong, LI Chun-mei, LIU Xiao-jun, YAO Hong. Hepatocyte-specific Sirt1 deficiency exacerbates liver inflammation of mice [J]. Basic & Clinical Medicine, 2022, 42(2): 282-285.
[12]	SHU Meng-xuan, YUAN Fang-chen, ZHOU Meng-qi, TU Shi-yan, XU Yue, QIN Hong-yan. Research progress in colitis-induced hepatic barrier dysfunction [J]. Basic & Clinical Medicine, 2022, 42(1): 149-153.
[13]	YU Bao-dan, CHEN Cong, KE Wu-jian, LYU Ping. Recombinant Treponema pallidum protein Tp47 increases permeability of vascular endothelial cells through inducing uPA [J]. Basic & Clinical Medicine, 2022, 42(1): 120-125.
[14]	YANG Yong, LI Zi-yu, YANG Wei, LIU Yong. Evaluation of inflammation of perirenal adipose tissue in C57BL/6J mice with high-fat diet [J]. Basic & Clinical Medicine, 2021, 41(9): 1318-1322.
[15]	YANG Xu-dong, YU Hong-liang, LI Jing, ZHAO Chun-hua. Macrophage J774A.1 exosome promotes the proliferation and migration of colorectal cancer cell lines MC38 and CT26 [J]. Basic & Clinical Medicine, 2021, 41(6): 799-804.